The differential levels of bile acids and bilirubin during the progression of MASLD may be due to the downregulation of the bile salt exchange protein (BSEP) in CLD with an upregulation of multi-drug resistant transport protein 2 (MRP2/ABCC2). The gene discussed is ABCB11; the disease is metabolic dysfunction-associated steatotic liver disease.